<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560937</url>
  </required_header>
  <id_info>
    <org_study_id>VA IRB# 00924</org_study_id>
    <nct_id>NCT00560937</nct_id>
  </id_info>
  <brief_title>Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia</brief_title>
  <official_title>Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durham VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durham VA Medical Center</source>
  <brief_summary>
    <textblock>
      This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The
      goal of this placebo-controlled study is to provide preliminary efficacy data for potential
      pregnenolone effects on cognitive symptoms and negative symptoms in patients with
      schizophrenia. Depressive symptoms and positive symptoms will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Score on the Scale for the Assessment of Negative Symptoms (SANS), p=0.048</measure>
    <time_frame>SANS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
    <description>The SANS assesses negative symptoms in schizophrenia. The SANS consists of 21 clinical interview questions assessing negative symptoms of schizophrenia. Each question is rated on a scale of 0 (no symptoms) to 7 (severe symptoms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change of Z-scores on the Brief Assessment of Cognition in Schizophrenia (BACS)</measure>
    <time_frame>Change in composite BACS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
    <description>The BACS includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. Z-scores are calculated from composite scores. Higher z-scores are indicative of better cognitive performance, lower z-scores are indicative of lower cognitive performance. Range of z-scores anticipated to be between -3 and 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)</measure>
    <time_frame>Change in composite MATRICS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
    <description>The MATRICS is a battery for the assessment of cognitive symptoms in patients with schizophrenia. Composite T-scores are calculated (T-score ranges are -20 to +80, and are normed on gender and age). Higher scores are indicative of better cognitive performance, lower scores are indicative of poorer cognitive performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Score Change in Calgary Depression Scale for Schizophrenia (CDSS)</measure>
    <time_frame>Change in CDSS scores at baseline and 8 weeks (at least 4 weeks; last observation carried forward)</time_frame>
    <description>The CDSS is used measure to investigate depressive symptoms in schizophrenia. The measure includes 9 questions ranked from 0 (no symptoms) to 3 (severe symptoms). Range of possible scores: 0-27.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale (CGI-I)</measure>
    <time_frame>CGI-I scores at 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
    <description>The CGI-I is a commonly used psychiatric scale to assess overall general improvement. The CGI-I consists of one interviewer-rated question on a scale of 1-7. Lower scores are indicative of fewer symptoms; while higher scores are indicative of more symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Score on the Positive and Negative Symptom Scale (PANSS)</measure>
    <time_frame>Change in PANSS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
    <description>The PANSS is a widely used measure with several subdomains, including positive symptoms, negative symptoms, and general psychopathology of schizophrenia. Lower scores are indicative of fewer symptoms; higher scores are indicative of more symptoms. Total PANSS scores range from 0-20.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregnenolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnenolone</intervention_name>
    <description>Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 years of age, any ethnic group, either sex

          2. Diagnostic and Statistical Manual, 4th edition (DSM IV) diagnosis of schizophrenia or
             schizoaffective disorder

          3. Ability to participate fully in the informed consent process, or have a legal guardian
             able to participate in the informed consent process.

          4. Patient cohort enriched for moderate to severe cognitive symptoms (composite Brief
             Assessment of Cognition in Schizophrenia (BACS) score 0-3 SD below the mean).

          5. No change in antipsychotic for 8 weeks or longer. No change in antipsychotic dose for
             4 weeks or longer.

          6. No change in anticholinergic, benzodiazepine, or mood stabilizer medications for 4
             weeks or longer.

          7. No anticipated need to alter any of the above medications (antipsychotics,
             anticholinergics, benzodiazepines, or mood stabilizers) for the 10-week duration of
             the study.

        Exclusion Criteria:

          1. Unstable medical illness or neurologic illness (seizures, cerebrovascular accident);
             history of prostate, breast, uterine, or ovarian cancer.

          2. Use of oral contraceptives or other hormonal supplementation such as estrogen.

          3. Other concomitant medications for medical conditions will be addressed on a
             case-by-case base to determine if exclusionary.

          4. Active expression of suicidal or homicidal ideation.

          5. Comorbid substance dependence (other than nicotine dependence), or presenting symptoms
             likely substance-induced, as judged by a study physician.

          6. Female patients who are pregnant or breast-feeding.

          7. Known allergy to study medication.

          8. Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone,
             clozapine, etc) will be excluded as suggested by the Federal Drug Administration
             (FDA); patients taking these agents will not be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine E Marx, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VAMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>November 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2010</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <name_title>Christine E. Marx, MD</name_title>
    <organization>Durham Veterans Affairs Medical Center</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Pregnenolone</keyword>
  <keyword>Cognition</keyword>
  <keyword>Negative Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment occurred between 8-05 and 4-06 for this single-site study at the Durham VAMC, Durham, NC.</recruitment_details>
      <pre_assignment_details>Following the screening visit, patients were withdrawn during the placebo lead-in phase and were not randomized for the following reasons: 1. hyponatremia, 2. hospitalization, 3.pneumonia, 4.no show for follow-up study visit, 5.chest pain, 6. elevated prolactin at baseline, 7.prolonged QTc at baseline</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pregnenolone</title>
          <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">One participant was withdrawn after 6 weeks and data were carried forward</participants>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregnenolone</title>
          <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="6"/>
                    <measurement group_id="B2" value="49" spread="12"/>
                    <measurement group_id="B3" value="51" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Score on the Scale for the Assessment of Negative Symptoms (SANS), p=0.048</title>
        <description>The SANS assesses negative symptoms in schizophrenia. The SANS consists of 21 clinical interview questions assessing negative symptoms of schizophrenia. Each question is rated on a scale of 0 (no symptoms) to 7 (severe symptoms).</description>
        <time_frame>SANS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
        <population>Pilot proof of concept study</population>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score on the Scale for the Assessment of Negative Symptoms (SANS), p=0.048</title>
          <description>The SANS assesses negative symptoms in schizophrenia. The SANS consists of 21 clinical interview questions assessing negative symptoms of schizophrenia. Each question is rated on a scale of 0 (no symptoms) to 7 (severe symptoms).</description>
          <population>Pilot proof of concept study</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.38" spread="10.18"/>
                    <measurement group_id="O2" value="-2.33" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-test of change scores, pregnenolone vs. placebo post-treatment compared to baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.048</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Score Change in Calgary Depression Scale for Schizophrenia (CDSS)</title>
        <description>The CDSS is used measure to investigate depressive symptoms in schizophrenia. The measure includes 9 questions ranked from 0 (no symptoms) to 3 (severe symptoms). Range of possible scores: 0-27.</description>
        <time_frame>Change in CDSS scores at baseline and 8 weeks (at least 4 weeks; last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score Change in Calgary Depression Scale for Schizophrenia (CDSS)</title>
          <description>The CDSS is used measure to investigate depressive symptoms in schizophrenia. The measure includes 9 questions ranked from 0 (no symptoms) to 3 (severe symptoms). Range of possible scores: 0-27.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="2.15"/>
                    <measurement group_id="O2" value="-2.00" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change of Z-scores on the Brief Assessment of Cognition in Schizophrenia (BACS)</title>
        <description>The BACS includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. Z-scores are calculated from composite scores. Higher z-scores are indicative of better cognitive performance, lower z-scores are indicative of lower cognitive performance. Range of z-scores anticipated to be between -3 and 3.</description>
        <time_frame>Change in composite BACS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Z-scores on the Brief Assessment of Cognition in Schizophrenia (BACS)</title>
          <description>The BACS includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. Z-scores are calculated from composite scores. Higher z-scores are indicative of better cognitive performance, lower z-scores are indicative of lower cognitive performance. Range of z-scores anticipated to be between -3 and 3.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.78"/>
                    <measurement group_id="O2" value="0.22" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)</title>
        <description>The MATRICS is a battery for the assessment of cognitive symptoms in patients with schizophrenia. Composite T-scores are calculated (T-score ranges are -20 to +80, and are normed on gender and age). Higher scores are indicative of better cognitive performance, lower scores are indicative of poorer cognitive performance.</description>
        <time_frame>Change in composite MATRICS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)</title>
          <description>The MATRICS is a battery for the assessment of cognitive symptoms in patients with schizophrenia. Composite T-scores are calculated (T-score ranges are -20 to +80, and are normed on gender and age). Higher scores are indicative of better cognitive performance, lower scores are indicative of poorer cognitive performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="8.87"/>
                    <measurement group_id="O2" value="7.00" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-test of change scores, pregnenolone compared to placebo post-treatment vs. pre-randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale (CGI-I)</title>
        <description>The CGI-I is a commonly used psychiatric scale to assess overall general improvement. The CGI-I consists of one interviewer-rated question on a scale of 1-7. Lower scores are indicative of fewer symptoms; while higher scores are indicative of more symptoms.</description>
        <time_frame>CGI-I scores at 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale (CGI-I)</title>
          <description>The CGI-I is a commonly used psychiatric scale to assess overall general improvement. The CGI-I consists of one interviewer-rated question on a scale of 1-7. Lower scores are indicative of fewer symptoms; while higher scores are indicative of more symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.33"/>
                    <measurement group_id="O2" value="2.89" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Score on the Positive and Negative Symptom Scale (PANSS)</title>
        <description>The PANSS is a widely used measure with several subdomains, including positive symptoms, negative symptoms, and general psychopathology of schizophrenia. Lower scores are indicative of fewer symptoms; higher scores are indicative of more symptoms. Total PANSS scores range from 0-20.</description>
        <time_frame>Change in PANSS scores at baseline and 8 weeks post-randomization (at least 4 weeks; last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnenolone</title>
            <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score on the Positive and Negative Symptom Scale (PANSS)</title>
          <description>The PANSS is a widely used measure with several subdomains, including positive symptoms, negative symptoms, and general psychopathology of schizophrenia. Lower scores are indicative of fewer symptoms; higher scores are indicative of more symptoms. Total PANSS scores range from 0-20.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.88" spread="9.23"/>
                    <measurement group_id="O2" value="-5.44" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during each study visit (study visits occurred every two weeks, a total of 5 study visits) for the duration of the 10 week study (following a 2 week placebo lead-in).</time_frame>
      <desc>Hillside Adverse Event Questionnaire used to obtain Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pregnenolone</title>
          <description>Pregnenolone 100 mg in divided doses (50 mg BID) for 2 weeks, then
Pregnenolone 300 mg in divided doses (150 mg BID) for 2 weeks, then
Pregnenolone 500 mg in divided doses (250 mg BID) for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo dosing and tablets were identical to Pregnenolone.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cold extremities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased interest in sex</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Impaired sexual performance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Excitation/agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain/stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation (date, address, mayor, MD name)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine E. Marx, MD, MA</name_or_title>
      <organization>Durham Veterans Affairs Medical Center</organization>
      <phone>919 286-0411 ext 7426</phone>
      <email>marx0001@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

